| 10/26/2021 |
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care | Financial Buzz |
financialbuzz.com |
... of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry. SimBioSys is also working in collaboration with 20 leading cancer institutions across the country to run clinical validation studies and recently published results from independent validation performed by prestigious cancer centers, demonstrating over 90 percent accuracy in predicting response to therapy in its first indication of early breast cancer.“We are honored ... |
| 10/19/2021 |
Reemo Health Enters Into Know-how Agreement With Mayo Clinic For Tech-enabled Cardiac Rehab And Maintenance |
PR Newswire |
MINNEAPOLIS Reemo Health, a connected health company specializing in home-based health management, today announced a know-how agreement with Mayo Clinic. This agreement will incorporate Mayo Clinic's expert clinical content, care pathways and clinical validation to Reemo's smartwatch-enabled cardiovascular programs. These home-based cardiac rehab and long-term cardiac maintenance programs are designed to improve patient enrollment, engagement and satisfaction as compared to traditional condition management offerings."Only ... |
| 10/16/2021 |
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021 |
itbusinessnet.com |
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021 – Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro – – Membrane proteome arrays screened with PLA2R CAAR candidates did not identify off-target interactions – – Pre-IND interaction ... |
| 10/15/2021 |
Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications |
Globe Newswire |
... October 18, 2021 to Friday, October 22, 2021.Talks featuring Bionano Genomics OGM solutions include research into how structural variation contributes to the cause of ALS; inverted genomic triplication structures; and a multi-site clinical validation study of constitutional postnatal SV, CNV and repeat array sizing, as well as findings of SVs in pediatric brain tumors, and epigenetics. Below is a list of customer presentations featuring OGM at this year ... |
| 10/15/2021 |
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021 |
Globe Newswire |
Äì Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro ‚Äì ‚Äì Membrane proteome arrays screened with PLA2R CAAR candidates did not identify off-target interactions ‚Äì ‚Äì Pre-IND interaction with the Food and Drug Administration (FDA) is planned for later this year for PLA2R-CAART preclinical candidate ‚Äì PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA ... |
| 10/15/2021 |
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021 |
Yahoo News |
Äì Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro ‚Äì‚Äì Membrane proteome arrays screened with PLA2R CAAR candidates did not identify off-target interactions ‚Äì‚Äì Pre-IND interaction with the Food and Drug Administration (FDA) is planned for later this year for PLA2R-CAART preclinical candidate ‚ÄìPHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA ... |
| 10/11/2021 |
|
malvern-online.com |
Veracyte, Inc . ( Nasdaq: VCYT ) today announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also show that the test delivers strong clinical performance across different nodule sizes and cancer stages in current or former smokers, and for patients who have already had other cancer ... |
| 10/11/2021 |
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment |
Yahoo News |
... test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosisSOUTH SAN FRANCISCO, Calif., October 11, 2021 --( BUSINESS WIRE )-- Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also show that the test ... |
| 10/11/2021 |
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment - Stocks News Feed |
stocksnewsfeed.com |
Company begins making novel, noninvasive test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosisSOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also ... |
| 10/11/2021 |
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment |
Business Wire |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also show that the test delivers strong clinical performance across different nodule sizes and cancer stages in current or former smokers ... |
| 10/11/2021 |
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Tests Ability to Improve Early Lung Cancer Assessment | Financial Buzz |
financialbuzz.com |
Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also show that the test delivers strong clinical performance across different nodule sizes and cancer stages in current or former smokers, and for patients who have already had other cancer ... |
| 10/8/2021 |
VR can take digital therapeutics to the next level—but clinical validation, cost, and murky reimbursement remain barriers to adoption - Insider Intelligence Trends, Forecasts & Statistics |
emarketer.com |
... equipment/deployment. VR headsets and software aren’t cheap, so providers that do decide to try VR-based DTx take on a high risk and uncertain return on their investments, especially given concerns around clinical validation of the tech). Reimbursement. More payers will need to step up to provide reimbursement pathways for VR DTx so that more doctors are willing to use the tech—but that’ll likely only happen ... |
| 10/7/2021 |
Todos and NLC Pharma report positive clinical data for Covid-19 test |
medicaldevice-network.com |
... test A steady inverse link between ct value and 3CL protease activity was found in hospitalised and non-hospitalised Covid-19 subjects. Todos Medical and its joint venture partner NLC Pharma have reported positive clinical validation data from a study where the former’s SARS-CoV-2 3CL protease biomarker assay, TolloTest, demonstrated complete sensitivity in detecting vaccinated asymptomatic Covid-19 patients. The study assessed the sensitivity of the test ... |
| 10/7/2021 |
Former Tilray CEO Joins Psychedelics Company |
Benzinga |
... and Organigram Holdings (NASDAQ: OGI ) has become the latest cannabis veteran to join the psychedelics industry, taking on the role of director at Clairvoyant Therapeutics.Clairvoyant is a Canadian biotech company focused on the clinical validation of psilocybin in the Canadian, U.K. and European Union markets.The company is currently on the road to receiving approval to begin a phase 2 trial on psilocybin for the treatment of alcohol use ... |
| 10/6/2021 |
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracytes Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease |
financialbuzz.com |
... cancer and interstitial lung disease (ILD) will be presented at the American College of Chest Physicians (CHEST) Annual Meeting 2021, being held virtually October 17-20, 2021.The abstracts include new data from an expanded clinical validation study which demonstrate the ability of Veracyte’s Percepta Nasal Swab test to determine cancer risk in patients with lung nodules found on CT scans – across lung nodule sizes, lung cancer stages and ... |
| 10/6/2021 |
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest‚Ñ¢, a Novel SARS-CoV-2 3CL Protease Biomarker Assay |
Globe Newswire |
... Oct. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, today announced positive clinical validation data for its 3CL protease biomarker assay TolloTest™ in a clinical study evaluating its sensitivity compared with PCR in hospitalized COVID-19 patients, patients hospitalized for conditions other than COVID-19 and individuals ... |
| 10/6/2021 |
Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation |
PR Newswire |
... free DNA (cfDNA) testing, announced the completion of the VALID Study ( V alidation for A llograft L ungs I mplementing D onor-derived cell-free DNA) for Prospera™ in lung transplant recipients. This clinical validation study has been accepted as a late-breaking abstract for presentation at the American College of Chest Physicians (ACCP) international online meeting, CHEST 2021, to be held on October 17–20, 2021.The prospective ... |
| 10/6/2021 |
Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation |
tncontentexchange.com |
... outcomes through genetic and cell-free DNA (cfDNA) testing, announced the completion of the VALID Study (Validation for Allograft Lungs Implementing Donor-derived cell-free DNA) for Prospera™ in lung transplant recipients. This clinical validation study has been accepted as a late-breaking abstract for presentation at the American College of Chest Physicians (ACCP) international online meeting, CHEST 2021, to be held on October 17–20, 2021. The prospective ... |
| 10/6/2021 |
Diadem Presents Data at 22nd International Conference on Alzheimer's Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging |
PR Newswire |
... The Diadem assay uses a proprietary antibody to measure blood levels of a conformational variant of the p53 protein (U-p53 AZ ) that has been implicated in the pathogenesis of AD.The presentation highlights clinical validation study data showing that a high concentration of U-p53 AZ is already detectable at the preclinical stage, years in advance of symptom onset in study individuals who progress to AD. It discusses the ... |
| 10/6/2021 |
Diadem Presents Data at 22nd International Conference on Alzheimer's Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging |
vporoom.com |
... Discovery . The Diadem assay uses a proprietary antibody to measure blood levels of a conformational variant of the p53 protein (U-p53AZ) that has been implicated in the pathogenesis of AD. The presentation highlights clinical validation study data showing that a high concentration of U-p53AZ is already detectable at the preclinical stage, years in advance of symptom onset in study individuals who progress to AD. It discusses the multiple ... |